Trial Profile
Phase I and Pharmacokinetics Study of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Jul 2015
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Sorafenib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 01 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 Dec 2009 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
- 30 Sep 2009 New trial record